relapsed non-Hodgkin lymphoma by autologous stem cell transplantation in patients with poor-risk or combination with high-dose etoposide and cyclophosphamide followed A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in

msra(2010)

引用 23|浏览38
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要